Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 first-in-human study of GC FLU and OVX836 influenza vaccine strategies in healthy adults
2026-526939-19-00Phase 2Authorised
- Sponsor
- Osivax
- Start
- Sep 2026
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of OVX836 + GC FLU, OVX836, GC Flu Quadrivalent and influenza vaccine in influenza (5 arms), sponsored by Osivax. Primary endpoints: Solicited local and systemic reactogenicity, Unsolicited adverse events and 3 more. Planned start Sep 2026; status: authorised.
02
Drugs
OVX836 + GC FLUOVX836GC Flu Quadrivalentinfluenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on 2026-526939-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526939-19-00.